Industry news
-
Pfizer to Acquire Biotech Firm Therachon in Deal Worth $810 Million
17 May 2019
Pfizer announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding, a privately held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS). The deal is worth $810 million.
-
Pfizer Selected First Drug Candidate From Pfizer-Sosei Alliance
16 May 2019
Pfizer has selected the first drug candidate from a collaboration with Sosei Group to develop drugs for major diseases, which are aimed at targets from the G protein-coupled receptor (GPCR) class.
-
Hey, big spender: Pharma's $6.6B TV ad outlay outranks most other industries, report says
16 May 2019
Pharma is the fourth-largest spender on TV ads in the U.S., with $6.6 billion spent over the past year. That’s according to MediaRadar’s annual study of TV ad spending, which includes OTC drug ads in its total that push it higher than other tallies.
-
Pharma TV ads get groovy with '70s rock soundtrack proliferation
15 May 2019
Pharma TV ads have been breaking out their boogie shoes lately. A handful of branded drug ads currently on the air are using popular ‘70s light rock songs to accompany their treatment messages, both to aid recall and to reach older audiences with music from their youth.
-
Pfizer Opened New Manufacturing Facility in USA
14 May 2019
Pfizer Inc. announced the opening of a new 175,000 square-foot manufacturing facility in Andover, Mass. Pfizer’s Andover site houses commercial manufacturing and product development functions, with colleagues dedicated to the development and production of high-quality complex biologics and vaccines. With its modular and flexible design, the newly opened Andover Clinical Manufacturing Facility (ACMF) will expand the capacity for Pfizer’s BioTherapeutics Pharmaceutical Sciences organization to manufacture clinical supplies.
-
Drug Spending in US Increased 4.5%
14 May 2019
Spending on all U.S. medicines increased 4.5% to $344 billion on a net price basis, despite lower price growth, due to higher patient use of new and protected brands, according to IQVIA Institute’s “Medicine Use and Spending in the U.S.: A Review of 2018 and Outlook to 2023″ report.
-
Need for Innovation in Antibiotic Development, Before It’s Too Late
13 May 2019
In a 2016 analysis of the deepening health threat posed by anti-microbial resistance (AMR), renowned economist Jim O’Neill predicted that by the year 2050, the number of deaths resulting from AMR will overtake those caused by cancer. Recommendations from O’Neill and his team on combatting the crisis were timely and aligned with governmental bodies, medical societies, health charities, and public health organizations.
-
The AI Patient Arc: Past, Present, Future
13 May 2019
An industry is a complicated network of connections between and among companies, customers and suppliers of goods and services. The transformation of any industry typically takes 30 to 50 years to complete and, as evidenced by how the Industrial Revolution impacted manufacturing and how Henry Ford’s assembly line impacted mass production, technology has always been a hallmark of such change.
-
FDA After Gottlieb: Thorny Issues, Political Challenges
08 May 2019
During the nearly two years that Scott Gottlieb headed FDA, the agency achieved record approval rates for new drugs and generics and advanced important innovations in clinical research and benefit/risk assessment to enhance R&D and competition in the biopharmaceutical industry. The agency issued multiple new rules and guidance documents and utilized important new authorities to expand staff expertise and agency capabilities. And Gottlieb successfully navigated the political pitfalls of Washington to gain increased funding for the agency and support for more aggressive action to promote public health.
-
The Role of Commercial Partners in Sales Strategy Development
08 May 2019
The pharmaceutical industry is in the midst of unprecedented change. Product portfolios are diversifying from mass market medications to include highly specialized therapies. Reimbursement is becoming more complex and successful commercialization means targeting multiple stakeholders before a prescription is even written.
